Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517230-17-00

Acronym

109883

Enrollment

Registered

2024-10-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracerebral haemorrhage

Brief summary

Oedema extension distance (OED) determined with MRI

Detailed description

(serious) Adverse events, Serum inflammatory markers IL-1β, IL-6, hsCRP, neutrophil and total white blood cell counts, DCE-MRI measurement of BBB transfer constant (Ktrans), mRS, Barthel index and EQ-5D-5L score

Interventions

DRUGANAKINRA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Oedema extension distance (OED) determined with MRI	—

Secondary

Measure	Time frame
(serious) Adverse events, Serum inflammatory markers IL-1β, IL-6, hsCRP, neutrophil and total white blood cell counts, DCE-MRI measurement of BBB transfer constant (Ktrans), mRS, Barthel index and EQ-5D-5L score	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026